Mixed trend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Mar 11 · inside the Ichimoku cloud · RSI 13 (oversold) · MACD above its signal · at its 52-week high
None of the 29 investors followed here reported a position in MRZM in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MRZM trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for MRZM.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 509.8 | 0.0 | -83.8 | -96.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −96.3% |
| 2024 | -0.1 | 1.0 | -12.4 | 7.4 | -2.1 | -41.8 | -7.8 | -14.0 | 16.4 | 11.9 | -10.6 | -83.6 | −91.8% |
| 2023 | -17.0 | 6.8 | -40.2 | -54.0 | -3.4 | -36.0 | 25.0 | 80.0 | 22.2 | -13.6 | -34.2 | -19.9 | −81.1% |
| 2022 | 4.5 | 5.4 | -0.5 | -1.5 | 20.9 | 16.5 | -1.1 | -10.2 | -20.5 | 0.0 | -41.1 | -52.7 | −70.1% |
| 2021 | 36.0 | 17.6 | -40.0 | -10.4 | -29.8 | -7.3 | -28.6 | 90.0 | -36.8 | 5.0 | 10.3 | 27.3 | −29.2% |
| 2020 | 438.5 | -8.0 | -51.5 | 61.6 | -40.1 | 65.3 | -7.5 | 0.5 | -19.9 | 34.2 | -10.0 | 38.9 | +380.8% |
| 2019 | 4.7 | 5.5 | -26.2 | -3.2 | 22.7 | -45.1 | -45.4 | -43.7 | 402.3 | -74.4 | 125.0 | -42.2 | −72.6% |
| 2018 | 0.0 | 0.0 | 162.5 | 161.9 | -10.9 | -38.7 | 54.9 | -59.6 | 100.9 | -29.2 | -15.5 | 45.0 | +309.5% |
| 2017 | 75.0 | 0.0 | -22.9 | 11.1 | 0.0 | -33.3 | -5.5 | -20.6 | 0.0 | 33.3 | -20.0 | 0.0 | −20.0% |
| 2016 | -5.1 | 5.4 | 12.5 | 0.0 | 66.7 | -40.0 | -7.8 | -1.0 | -27.0 | 8.3 | 3.1 | -70.1 | −75.0% |
| 2015 | -6.9 | 11.1 | -26.7 | 4.5 | -4.3 | 9.1 | 8.3 | -30.8 | -2.2 | -7.9 | 4.8 | -5.9 | −44.8% |
| 2014 | 0.0 | 67.3 | -60.2 | 28.0 | -14.1 | 50.0 | -21.2 | -15.4 | 27.3 | -3.6 | 22.2 | -12.1 | −3.3% |
| 2013 | -40.4 | 34.2 | 0.0 | -49.5 | 23.8 | 0.0 | -32.0 | 28.8 | -4.1 | -9.5 | -5.3 | -16.7 | −70.0% |
| 2012 | 4.4 | -22.9 | -12.1 | -29.0 | -56.3 | -11.1 | -12.5 | -14.3 | -13.3 | -23.1 | -10.0 | 177.8 | −75.6% |
| 2011 | 5.6 | 13.7 | 128.2 | -8.7 | -3.8 | -7.6 | -22.5 | -29.0 | -6.8 | 24.4 | -19.6 | 0.0 | +13.9% |
| 2010 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1583.3 | 78.2 | +2900.0% |
| 2009 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2008 | 20.0 | 0.0 | +20.0% |
No analyst coverage for this instrument.
Marizyme, Inc., a multi-technology life science company, engages in the research, manufacture, and commercialization of medical devices, diagnostics, and products to address clinical needs in the United States, Europe, and Asia. The company operates as a medical technology company that delivers solutions for coronary artery bypass graft surgery. Its product portfolio includes DuraGraft, a biocompatible intraoperative vascular graft storage and flushing solution; and Krillase, an enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, and dental care and thrombosi, as well as MATLOC 1, a lab on chip digital device, which is under development for screening of individuals at risk for the development of chronic kidney disease. The company also engages in the development of MAR-FG-001, a fat grafting technology for fat grafting procedures. The company was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018. The company was incorporated in 2007 and is based in Jupiter, Florida.
No recent headlines.